Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer

Table 2 Comparison of the tumor marker levels between the two groups before and after treatment (mean ± SD)

Group	CEA (ng/mL)		CA199 (U/mL)		TPS (U/L)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
FLOT group (n = 42)	40.16 ± 8.84	33.79 ± 5.76a	45.76 ± 10.14	24.07 ± 4.67a	160.27 ± 31.69	47.63 ± 5.09a
SOX group (n = 42)	39.41 ± 8.23	37.31 ± 7.64a	46.51 ± 10.63	29.74 ± 6.52a	162.34 ± 27.32	62.31 ± 7.62a
t-value	0.402	2.384	0.331	4.582	0.321	10.382
P value	> 0.05	< 0.05	> 0.05	< 0.05	> 0.05	< 0.05

^aP < 0.05, when compared with the pre-treatment group.

CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; TPS: Peptide tissue antigen.